Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Matinas Biopharma Hl (MTNB)

Matinas Biopharma Hl (MTNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards GlobeNewswire - Fri Apr 3, 4:00PM CDT

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”)...

MTNB : 0.5030 (+0.60%)
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors GlobeNewswire - Tue Mar 11, 2025

GRCE : 3.82 (+6.41%)
ONVO : 2.04 (+1.49%)
MTNB : 0.5030 (+0.60%)
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors GlobeNewswire - Thu Feb 13, 2025

MTNB : 0.5030 (+0.60%)
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair GlobeNewswire - Fri Feb 7, 2025

MTNB : 0.5030 (+0.60%)
Matinas BioPharma Receives NYSE Noncompliance Notice GlobeNewswire - Fri Jan 10, 2025

MTNB : 0.5030 (+0.60%)
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction GlobeNewswire - Thu Oct 31, 2024

MTNB : 0.5030 (+0.60%)
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress Globe Newswire - Thu Aug 11, 2022

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility...

MTNB : 0.5030 (+0.60%)
Matinas BioPharma to Participate in the BTIG Biotechnology Conference Globe Newswire - Mon Aug 1, 2022

BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.5030 (+0.60%)
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022 Globe Newswire - Thu Jul 28, 2022

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical...

MTNB : 0.5030 (+0.60%)
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis Globe Newswire - Mon Jul 25, 2022

BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.5030 (+0.60%)

Barchart Exclusives

Ignore the Anthropic Panic and Keep Buying Palantir Stock, Says Wedbush Barchart - Mon Apr 13, 3:53PM CDT
Wedbush urges investors to tune out the Anthropic noise and keep buying Palantir, betting on its strong AI moat and solid fundamentals. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.